# Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

> **NCT00254423** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 150 (actual)

## Conditions studied

- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00254423
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-08
- **Primary completion:** 2025-03-14
- **Final completion:** 2025-03-14
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254423, "Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00254423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*